Decades o p blic and pri ate in estment in cancer biolog research has led to an enhanced nderstanding o the ndamental genetic changes that lead to the ormation and progres sion o cancer . Clinical scientists ha e or ed iterati el o er this same period to de elop n anced chemotherap regimens that ha e either e tended s r i al e pectations or most patients ith common t pes o cancer, or in the cases o pediatric cancers, germ cell t mors, and some hematologic malignancies, e ected c res. The last decade in partic lar has itnessed a period o intense prod cti it in the de elop ment o molec larl targeted therapies man o these agents ha e prod ced impressi e and s stained tho gh not et c rati e bene its in de ined s bgro ps o patients, at least ntil resistance de elops. Most recentl , therapies rooted in no ledge o cancer imm nolog ha e sho n promising res lts in s bgro ps that are not ell ser ed b e isting c toto ic and tar geted therapies these ad ances are highl li el to pla a more meaning l role in the oncolo gist s t re armamentari m . n alone, the FD appro ed ne molec lar entities or biologic agents or the treatment o cancer, rep resenting a third o FD appro als across all ther ape tic classes . O er the last t o ears, the n mber o cancer appro als ar e ceeded those in all other ields. t is no possible or all b t the most s eptical obser ers to en ision an enco r aging path or ard.
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One estion that arises implicitl rom this positi e d namic is hether the oncolog com m nit , partic larl in the nited tates, has prepared or s ccess. a e e de eloped s s tems to e al ate comprehensi el ne thera pies in real orld settings re e ro tinel generating the e idence that can help red ce practice ariations and impro e health o t comes in lnerable gro ps re e appl ing the ne therapies in the most appropriate set tings, directing them primaril to patients most li el to recei e a bene it a e e re ined methods that can estimate the al e both clini cal and economic o ne therapies compared to the clinical pro iles and costs o re erence standards Complicating the matter rther is the realization that oncolog s er s ccess, no and in the t re the direct res lt o one o the most prod cti e p blic pri ate partner ships in merican histor is threatened b iscal b dget constraints at the er same time that cancer care costs threaten the iscal health o the nited tates. The ational Cancer nsti t te estimates, sing conser ati e ass mp tions, that the real costs o cancer care in the nited tates ill increase at least o er the period rom to and ma e ceed billion constant c rrenc b the end o the decade . These cancer care costs, hich are gro ing aster than costs in other areas o medicine, ill comprise a s bstantial portion o the Medicare and Medicaid b dgets that ha e been cited b at least one ma or ratings agenc as sti ication or the loss o merica s credit rating ith rther do ngrades possible.
Comparati e e ecti eness research C R , the latest name gi en to e orts that began in the s to impro e alit and ma imize the al e o health ser ices, o ers a s stem atic approach to addressing the conundrum brought upon b oncolog s success. C R has been used in most de eloped countries to a greater or lesser e tent to ma e e idence based unding decisions and to ormulate treat ment guidelines , . ndeed, the current en ironment should be ielding enthusiasm or the implementation o C R, et the ield has struggled to de ine its role ithin the merican cancer communit .
The challenges or C R ha e been mani old. First, the enormit o the tas re uired to de elop e ecti e treatments has di erted attention understandabl rom some o the more conte tual uestions that C R see s to address. Critical in uir into the relati e eco nomic alue o ne treatments has not neces saril been encouraged as oncologists right ull pushed or greater inno ation. econd, until relati el recentl , the cost o cancer care has been minor hen compared to other lphaMed Press picture o an agent s promise. uestions such as ho a drug ill per orm hen gi en to broader patient populations, its longer term sa et and e ecti eness pro ile, and its broader impact on patient care and outcomes (including economic outcomes are usuall le t unans ered b trialists, e en ell a ter appro al. Comparati e e ecti eness researchers ha e the opportunit to ill this broad e idence gap . Ramse and colleagues con ened o er i teen sta eholders repre senting a broad arra o perspecti es o er a t o da period to discuss i e themes in the C R ield. The group addressed directl the reasons h C R has ound a limited audience in the nited tates and made speci ic recommendations or impro ement.
O the i e areas on hich the group ocused, three ere most illuminating: the need to consider cost in C R, separat ing ell conducted rom poorl conducted C R, and better reporting to meet the needs o bus decision ma ers. t as interesting that all sta eholders elt that cost is a ital issue or C R, despite the current political en ironment that dis courages cost e ecti eness in go ernment unded C R. The group also presented suggestions or better reporting and identi ied i e isses o death hen publishing C R, such as e tensi e use o technical argon ending ith ambiguous conclusions and a comparison group that consists o out moded treatments or incomparable patient populations. This part o Ramse et al. s article should be re uired reading or an outcomes researcher planning to submit an article or publication in an oncolog ournal. e eral o the sta ehold ers suggested the need to de elop a chec list eri ing the methodological issues that ere addressed in the C R stud (such as e orts to identi and reduce bias and the establish ment o a prospecti e C R registr that ould re uire com pletion o such a chec list. This group should be commended or its open discussion about h C R has recei ed relati el modest acceptance and or its clear and speci ic recommen dations to mo e the ield or ard.
Loo ing bac o er the last ears or so, the s stem has or ed. nno ation has happened the pace o prog ress is accelerating. The combination o monopol pricing or cancer drugs in the nited tates (during mar et e clu si it and ederal la that re uires Medicare to co er an drug used in an anticancer regimen or a medicall accepted indication has produced the potential or abnormall high returns or sponsors in esting in cancer drug de elopment. This return potential, including a so called inno ation pre mium, has created po er ul incenti es that could sustain the large and prolonged in estment re uired to und the ris business o cancer drug de elopment. The rise in the cost o cancer care cost has been seen as the price o this inno ation . t is less clear toda ho much longer soci et is illing to support these costs, and it is an arithmetic certaint that the rate o gro th in cancer costs is unsus tainable. the situation is le t unchec ed, and ultimatel gets politicized, the outcome is li el to be unpredictable and suboptimal. The recent mandator across the board budget cuts no n as the se uester, in hich the bud get o the ational nstitutes o ealth as slashed b . billion and Medicare reimbursement cut b , ma pro ide an e ample o ho blunt polic instruments could be applied to cancer unding in the uture.
areas o medicine and has largel escaped scrutin in the nited tates. e ore the de elopment o paclita el in the s, cancer care had a negligible impact on national bud gets: e e ecti e treatments e isted once disease spread be ond primar sites, and patients ho could not be cured ere encouraged to see supporti e care at relati el mod est costs. Third, mericans ha e sho n neither a cultural a init nor a political interest in C R, especiall as it applies to issues o healthcare costs. The recentl enacted Patient Protections and ordable Care ct ( C in act created and unded an entit to conduct C R, the Patient Centered Out comes Research nstitute (PCOR , et e pressl prohibited it rom per orming cost e ecti eness research . Finall , the research itsel has su ered rom important limitations as outcomes researchers ha e sought to generate timel , rel e ant, unbiased, and scienti icall alid e idence that sta e holders could use to impro e real orld decisions. hile oncologists ha e gro n accustomed to high ualit e icac studies ith clear cut outcomes, man o the C R studies, in contrast, ha e relied on obser ational data or re uired the incorporation o numerous assumptions based on incom plete data, and some model outputs ha e been criticized or alse precision. ll can agree on the appeal and commend able goals o C R, et some o the publications in this area ha e de ol ed in highl technical methodological e ercises that are poorl understood b the ultimate consumers o the research, thereb lessening their impact.
This bac drop pro ides a recepti e conte t or t o important papers published in this issue o The Oncologist, each led b prominent igures in the ield, Gar L man and cott Ramse , . Together, these articles ad ance a clear e planation o the goals, tools, and limitations o C R and call on oncologists to lead the discourse on the comparati e alue o cancer care options. Gar L man ma es three notable points. First, he de ines succinctl hat C R is and hat it is not. L man describes C R as stri ing to de ine the optimal strategies or deli ering the most e ecti e and sa e inter entions to appropriate popula tions in the most e icient a . e e pressl di erentiates this goal rom rationing, restrictions, and cost containment.
econd, L man lists and discusses the tool it o outcomes researchers, demonstrating the breadth o the C R ield hile discussing the promise, limitations, and uture oppor tunities o each methodolog . is table, hich lists the or in progress or each o the methodologies, such as the Can cerLin e orts o the merican ociet o Clinical Oncolog ( CO , ill li el pro ide a roadmap or the ield o er the ne t ears. Finall , Dr. L man e plains ho C R ma e tend its reach to helping ad ance the promise o personalized and genomic medicine gi en the need or earl and continuous statistical o ersight and gi en the ariable ualit o research in this area, hich in his ie , is all too o ten lac ing.
hile Dr. L man produced a clear description o the ield and a roadmap or its uture, the group led b cott Ramse ent urther. Ramse and colleagues pro ide one o the most reasonable and practical prescriptions to date or ho the ield o C R ma mo e or ard and realize its promise. The Ramse paper irst describes the opportunit or C R. imilar to L man, the authors note that the established phase trial process in oncolog pro ides an incomplete Roberts TheOncologist.com lphaMed Press www.TheOncologist.com
The articles b L man and Ramse et al. pro ide optimism that the tools related to C R can help impro e outcomes and a oid waste in a more intelligent wa . There is also e i dence elsewhere to suggest that ph sicians, and not politi cians, are leading this debate as it relates to oncolog . te en Pearson and Peter ach, or e ample, ha e articulated a straight orward and relati el simple idea o how Medicare could use C R in deciding on new co erage and reimburse ment . lsewhere, more than leading cancer special ists ha e oined together to protest high drug costs, as the ha e pointed out that more than o the cancer drugs that recei ed FD appro al last ear cost in e cess o , per ear . The merican ociet o Clinical Oncolog has recentl identi ied i e e opportunities to impro e care and reduce costs and is in esting in a rapid learning s stem which ma help oncologists, among man other things, incor porate more e ecti el these and other ualit initiati es . Other prominent oncologists ha e called or cost and comparati e alue o treatment to be considered in clinical practice guidelines.
mportantl , no ph sician has argued that it is appropriate or indi idual oncologists to ma e rationing decisions at the bedside. Finall , e orts b transla tional researchers to identi subsets o patients most li el to bene it rom e isting and uture treatment will no doubt pla an important role in impro ing the uture alue proposi tion o cancer treatments.
Longer term, C R will pla a e role in e orts to optimize outcomes or cancer patients gi en societ s inite willing ness and abilit to pa , but onl when there is greater political and social acceptance o the ield and hope ull when it has a trusted administrati e conte t in which organization and content decisions are made independentl rom its unding source . The oncologist communit has a distinguished histor o leading research in comparati e e ecti eness dat ing bac to the irst randomized trials in acute leu emia in the s. Oncologists ha e shown that the can come together or the bene it o patients in a wa that elected representa ti es cannot. ow is the time or the oncolog communit to ta e more concrete steps to ad ance the ision that 
